Company news

Gilead Sciences, Inc. news in 2024

Gilead Sciences, Inc.'s news releases, calls and decks from 2024, newest first.

View company

U.S. FDA Grants Breakthrough Therapy Designation to Trodelvy® (sacituzumab govitecan-hziy) for Second-Line Treatment of Extensive-Stage Small Cell Lung Cancer

December 16, 2024

Gilead and Terray Therapeutics Announce Multi-Target Research Collaboration to Discover and Develop Novel Small Molecule Therapies

December 16, 2024

Gilead’s Seladelpar Receives Positive CHMP Opinion for Primary Biliary Cholangitis

December 12, 2024

Gilead Sciences Appoints Dietmar Berger, MD, PhD, as Chief Medical Officer

December 11, 2024

Longest Follow-Up Data Reported for Kite’s Tecartus® CAR T-Cell Therapy at ASH 2024 Reinforce Durable Efficacy and Survival Benefits

December 8, 2024

Kite’s Yescarta® Only CAR T-Cell Therapy to Show Durable Response and Long-Term Survival After Five Years in Patients With Relapsed/Refractory Non-Hodgkin Lymphomas at ASH 2024

December 8, 2024

Kite Presents New Data Underscoring Curative Potential of Yescarta® in Relapsed/Refractory Large B-cell Lymphoma at ASH

December 7, 2024

Gilead and Tubulis Enter Into Exclusive Option and License Agreement to Develop ADC Candidate for Select Solid Tumor Target

December 2, 2024

Gilead Announces New England Journal of Medicine Publication of PURPOSE 2 Results

November 26, 2024

Gilead’s Livdelzi (Seladelpar) Demonstrated a Sustained Efficacy and Long-Term Safety Profile in Management of Primary Biliary Cholangitis

November 14, 2024

Gilead Prices $3.5 Billion of Senior Unsecured Notes

November 12, 2024

Gilead Presents Full PURPOSE 2 Data Results for Twice-Yearly Lenacapavir for HIV Prevention at HIV Glasgow

November 12, 2024

Scientific Leadership Spotlighted as Gilead Presents Research Data Across Its Broad and Innovative HIV Treatment Portfolio and Pipeline

November 11, 2024

Gilead Sciences to Present at Upcoming Investor Engagements

November 7, 2024

Late-Breaking Clinical Data and Real-World Evidence Presented at HIV Glasgow as Gilead Extends Leadership Efforts Toward Ending the Epidemic

November 6, 2024

Gilead Sciences Announces Third Quarter 2024 Financial Results

November 5, 2024

Kite to Highlight Industry-Leading CAR T-Cell Therapy Portfolio at ASH 2024, Including Positive Survival Outcomes in Both Clinical Trials and the Real-World

November 4, 2024

Gilead to Present Latest Research Across Key Liver Disease Indication at the American Association for the Study of Liver Disease (AASLD) Meeting 2024

October 21, 2024

Gilead and Merck Announce Phase 2 Data Showing a Treatment Switch to an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression in Adults at Week 48

October 18, 2024

Gilead Sciences to Release Third Quarter 2024 Financial Results on Wednesday, November 6, 2024

October 8, 2024

Gilead to Present Late-Breaking Data Highlighting Antiviral Portfolio, Innovative Research Pipeline and HIV Leadership at IDWeek 2024

October 8, 2024

Gilead Presents Additional Efficacy, Safety and Demographic Data From PURPOSE 2 Trial at 5th HIV Research for Prevention Conference

October 6, 2024

Gilead Signs Royalty-Free Voluntary Licensing Agreements With Six Generic Manufacturers to Increase Access to Lenacapavir for HIV Prevention in High-Incidence, Resource-Limited Countries

October 1, 2024

Gilead’s Twice-Yearly Lenacapavir for HIV Prevention Reduced HIV Infections by 96% and Demonstrated Superiority to Daily Truvada® in Second Pivotal Phase 3 Trial

September 11, 2024

Gilead and Genesis Therapeutics Announce Strategic Collaboration to Discover and Develop Novel Therapies

September 9, 2024

Gilead to Present New Trodelvy® Data at the IASLC 2024 World Conference on Lung Cancer

September 4, 2024

Gilead’s Livdelzi (Seladelpar) Granted Accelerated Approval for Primary Biliary Cholangitis by U.S. FDA

August 13, 2024

Gilead Sciences Announces Second Quarter 2024 Financial Results

August 7, 2024

Gilead Sciences to Release Second Quarter 2024 Financial Results on Thursday, August 8, 2024

July 24, 2024

Gilead Presents Research Data Across Its Broad and Innovative HIV Treatment Portfolio and Pipeline

July 24, 2024

Full Efficacy and Safety Results for Gilead Investigational Twice-Yearly Lenacapavir for HIV Prevention Presented at AIDS 2024

July 23, 2024

Gilead and the Elton John AIDS Foundation Announce Additional Five Years of RADIAN Partnership to Help Address the Growing HIV Crisis in Eastern Europe and Central Asia

July 21, 2024

Chief Medical Officer Merdad Parsey to Leave Gilead Early 2025

July 16, 2024

Gilead to Highlight Landmark Progress in Research Across HIV Prevention, Treatment and Cure Programs at AIDS 2024

July 15, 2024

Gilead’s Twice-Yearly Lenacapavir Demonstrated 100% Efficacy and Superiority to Daily Truvada® for HIV Prevention

June 19, 2024

New Kite Clinical Research and Real-World Evidence for Yescarta® Demonstrate Benefit From Earlier Lines of Treatment

June 13, 2024

Gilead Announces New England Journal of Medicine Publication of Data that Demonstrate Bulevirtide with PegIFN Achieved Post-Treatment Undetectable HDV RNA

June 5, 2024

Gilead’s Seladelpar Demonstrated a Sustained and Consistent Long-Term Efficacy and Safety Profile in Primary Biliary Cholangitis

June 4, 2024

Kite’s Tecartus® Demonstrates Sustained Overall Survival in Adult Patients With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia

June 2, 2024

Encouraging New Data Presented on Kite’s Yescarta® for Relapsed/Refractory Central Nervous System Lymphoma

June 2, 2024

Gilead and Arcus Announce Etrumadenant Plus Zimberelimab Regimen Significantly Reduced the Risk of Death in Third-line Metastatic Colorectal Cancer

June 1, 2024

Gilead and Arcus Announce Anti-TIGIT Domvanalimab Plus Zimberelimab and Chemotherapy Exceeded One Year of Median Progression-Free Survival as a First-Line Treatment for Upper GI Cancers

May 31, 2024

EVOKE-01 Study Results in Metastatic NSCLC to Be Presented at an Oral Session at ASCO 2024

May 30, 2024

Gilead Provides Update on Phase 3 TROPiCS-04 Study

May 29, 2024

Gilead to Present Latest Research Across Key Liver Disease Indications at the European Association for the Study of the Liver Congress 2024

May 21, 2024

Investigational Seladelpar Demonstrates Significant Improvements in Liver Disease Progression and Reduced Itching in Primary Biliary Cholangitis

May 17, 2024

Kite Data at EHA 2024 Demonstrate Positive Patient Outcomes and Advances in Delivery of CAR T-cell Therapy

May 13, 2024

Kite and Arcellx Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program

May 8, 2024

Gilead and Kite Oncology to Highlight Broad and Diverse Oncology Portfolio at ASCO 2024

May 6, 2024

FDA Approves Biktarvy® Label Update With Data for Pregnant Adults With HIV

April 25, 2024

Older news releases →

Calls in 2024

Decks in 2024